Qilu Pharmaceutical Co., Ltd. clinical trial pipeline

5 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 3 with minor changes only.

1. Notable

   QLS31905 in Combination With CAPOX Versus Sintilimab in…QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment · GC/GEJ

   Primary endpoint(s) modified

   Also in this update: Recruitment opened

   Qilu Pharmaceutical Co., Ltd.·Phase 3· NCT07716449· Registry history of NCT07716449 on ClinicalTrials.gov (opens the registry)

   Oct 19, 2026

2. Notable

   QLS2319 in Healthy Subjects and Cancer Cachexia

   Recruitment opened

   Qilu Pharmaceutical Co., Ltd.·Phase 1/2· NCT07735104· Registry history of NCT07735104 on ClinicalTrials.gov (opens the registry)

   Sep 25, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.